-
ScienceDaily
Feb 27, 2015, 6:13 pm43 ptsAbout 10 percent of patients with chronic lymphocytic leukemia discontinued therapy with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical trials, according to a new study.
Trending Today on EcoTopical
Welcome to EcoTopical Your daily eco-friendly green news aggregator.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.
Leaf through planet Earths environmental headlines in one convenient place. Read, share and discover the latest on ecology, science and green living from the web's most popular sites.